When used as an ancillary, it can be taken by male athletes and bodybuilders all throughout their cycle length at 50 – 100mg per day, as there is no limit to how long it can be utilized for. Some individuals prefer to also run Proviron as a PCT (Post Cycle Therapy) drug in order to reduce Estrogen levels and boost fertility. Although this can be done, there are much better compounds with similar (and stronger) effects for PCT. When the risk of even weak endogenous Testosterone suppression is thrown into the mix with Proviron, it is advised to avoid the use of Proviron for PCT purposes unless there are no other options available. During a period in which individuals are attempting to recover their natural endogenous Testosterone levels, any threat no matter how minimal to endogenous Testosterone production should be unwelcome and avoided at all costs.
Two hundred fifty subfertile men with idiopathic oligospermia (count less than 20 million/ml) were treated with mesterolone (100-150 mg/day) for 12 months. Seminal analysis were assayed 3 times and serum follicle stimulating hormone (FSH) luteinizing hormone (LH) and plasma testosterone were assayed once before treatment and repeated at 3, 6, 9 and 12 months after the initiation of treatment. One hundred ten patients (44%) had normal serum FSH, LH and plasma testosterone, 85 patients (34%) had low serum FSH, LH and low plasma testosterone. One hundred seventy-five patients (70%) had moderate oligospermia (count 5 to less than 20 million/ml) and 75 patients (30%) had severe oligospermia (count less than 5 million/ml). Seventy-five moderately oligospermic patients showed significant improvement in the sperm density, total sperm count and motility following mesterolone therapy whereas only 12% showed improvement in the severe oligospermic group. Mesterolone had no depressing effect on low or normal serum FSH and LH levels but had depressing effect on 25% if the levels were elevated. There was no significant adverse effect on testosterone levels or on liver function. One hundred fifteen (46%) pregnancies resulted following the treatment, 9 of 115 (%) aborted and 2 (%) had ectopic pregnancy. Mesterolone was found to be more useful in patients with a sperm count ranging between 5 and 20 million/ml. Those with severe oligospermia (count less than 5 million) do not seem to benefit from this therapy.